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Abstract: The aim of this review is to understand how physical activity and nutrition are involved in
the improvement of sarcopenia in patients affected by liver cirrhosis. The pathogenesis of sarcopenia
in cirrhosis involves three major factors: inadequate dietary intake, metabolic disturbances, and
malabsorption. Although in the early stages muscles appear to be spared, sarcopenia progressively
leads to mobility limitations and its consequences, such as propensity to falls and drastically reducing
life quality. Several studies confirm the important role played by physical activity and balanced
nutrition in this chronic condition. Exercise and nutritional intervention should be recommended in
these patients in order to improve quality of life.
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1. Introduction
Cirrhosis of the liver is responsible for 13.7%–14.7% of age-standardized death rates across the
world. The onset of the condition results from chronic or long-lasting aetiological factors such as
long-term excess alcohol consumption, infectious diseases like hepatitis B and C, and non-alcoholic
fatty liver diseases (NAFLD), usually arising as a result of the metabolic syndome [1]. Patients with
end-stage liver disease show a higher prevalence of malnutrition, which is associated with increased
morbidity and mortality [2]. Clinical complications are in part due to generalized tissue wasting,
especially the loss of muscle mass [2]. Patients with more advanced cirrhosis are catabolic and are
usually significantly affected by malnutrition and sarcopenia as a result.
Energy balance (EB) is composed of energy intake and energy expenditure. A correct EB is closely
related to healthy weight maintenance. When food intake is less than energy expenditure (negative
EB), the depletion of energy stores and consequent weight loss have a negative effect on patient
outcome [2].
The liver plays an essential role in the supply, passage and metabolism of essential nutrients like
proteins, fat and carbohydrates to all parts of the body. If this process is altered, all the functional
properties of the liver are impaired and the effect is an increased protein catabolism, decreased hepatic
and skeletal muscle glycogen synthesis and finally increased lipolysis [3]. Therefore, chronic liver
disease undernutrition, due to dietary restriction, altered nutrient biosynthesis and modified intestinal
absorption, is responsible for an enhanced protein loss and pro-inflammatory cytokine levels, resulting
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in a catabolic state [3] with myopathies and general sarcopenia. Such sarcopenia is associated not only
with the aggravation of other complications of cirrhosis such as ascites, hepatic encephalopathy, and
portal hypertension, but also with NAFLD in individuals affected by metabolic syndrome [4,5]. Loss of
muscle mass directly contributes to exercise intolerance and impaired activities of daily living, which
makes it a strong determinant of quality of life and subsequent mortality [6]. Indeed, the survival rate
in patients with sarcopenia is significantly lower than in patients without sarcopenia [5]. The aim of
this narrative review is to explore the interrelationship between sarcopenia and liver disease and the
possible beneficial role of nutrition and physical activity.
2. Sarcopenia
Sarcopenia is a syndrome characterised by progressive and generalized loss of skeletal muscle
mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life
and, ultimately, death [7]. Although the primary cause of muscle depletion is aging, sarcopenia
can also occur in patients with chronic disease, particularly in end-stage liver disease. The most
typical symptom of sarcopenia is muscle wasting, defined as a progressive and generalized loss of
muscle mass [8]. The first manifestation of sarcopenia is atrophy: the muscle progressively reduces
its size, muscle fibres are replaced by fat and fibrous tissue, with increased oxidative stress, muscle
metabolism changes, and neuromuscular junction degeneration arises, leading to progressive loss of
muscle function and frailty [8,9]. For the diagnosis of sarcopenia, the European Working Group on
Sarcopenia in Older People recommends using the presence of both low muscle mass and reduced
muscle function (strength or performance). Several techniques can be used to quantify muscle mass,
including three imaging techniques: computed tomography, magnetic resonance imaging and dual
energy X-ray absorptiometry. However, there are fewer well-validated tools to assess muscle strength.
Handgrip strength is widely used and correlates well with most relevant outcomes, although the lower
limbs are more important than the upper limbs for gait and physical function. Furthermore, to assess
physical performance, a wide range of tests are used, including the Short Physical Performance Battery,
usual gait speed, 6-min walk test and the stair climb power test [7].
The pathogenesis of sarcopenia in cirrhosis has three major contributory causes: inadequate
dietary intake, metabolic disturbance and malabsorption. There are several factors responsible for
an altered dietary intake in patients with cirrhosis. Some report nausea, early satiety and loss of
appetite. This commonly depends on the presence of ascites, upregulation of leptin and tumor
necrosis factor-α [10] and zinc deficiency, which is usually responsible for altered taste sensation [11].
Altered visceral motility, and the overgrowth of small intestinal bacteria are also very common [12].
Sodium restriction, decreased protein intake and iatrogenic fasting during hospitalization contribute
to aggravating poor oral intake (Figure 1).
J. Funct. Morphol. Kinesiol. 2016, 1, 118–125  119 
pro-inflamm tory cytokine levels, resulting in  c tabolic state [3] with myopathies and general 
sarcopenia. Such sarcopenia is asso iated n t only with the ggravation of oth r omplications of 
cirrhosis such as ascites, hepatic encephalopathy, and portal hypertension, but also with NAFLD in 
individuals affected by metabolic syndrome [4,5]. Loss of muscle mass directly contributes to 
exercise intolerance and impaired activities of daily living, which makes it a strong determinant of 
quality of life and subsequent mortality [6]. Indeed, the survival rate in patients with sarcopenia is 
significantly lower than in patients without sarcopenia [5]. The aim of this narrative review is to 
explore the interrelationship between sarcopenia and liver disease and the possible beneficial role of 
nutrition and physical activity. 
2. Sarcopenia 
Sarcopenia is a syndrome characterised by progressive and generalized loss of skeletal muscle 
mass and strength with a risk of adverse outcomes such as physical disability, poor quality of life 
and, ultimately, death [7]. Although the primary cause of muscle depletion is aging, sarcopenia can 
also occur in patients with chronic disease, particularly in end-stage liver disease. The most typical 
symptom of sarcopenia is muscle wasting, defined as a progressive and generalized loss of muscle 
mass [8]. The first manifestation of sarcopenia is atrophy: the muscle progressively reduces its size, 
muscle fibres are replaced by fat and fibrous tissue, with increased oxidative stress, muscle 
metabolism changes, and neuromuscular junction degeneration arises, leading to progressive loss 
of muscle function and frailty [8,9]. For the diagnosis of sarcopenia, the European Working Group 
on Sarcopenia in Older People recommends using the presence of both low muscle mass and 
reduced muscle fu ction (strength or performance). Several techniq es can be used to quantify 
muscle mass, including t ree imaging techniques: computed tomography, magnetic reso ance 
imaging and dual energy X-ray absorptiometry. Howev r, there are fewer well-validated tools to 
assess muscle strength. Handgrip strength is idely used and correlates well with most relevant 
outcomes, although the lower limbs are more important than the upper limbs for gait and physical 
function. Furthermore, to assess physical performance, a wide range of tests are used, including the 
Short Physical Performance Battery, usual gait speed, 6-min walk test and the stair climb power test 
[7]. 
The pathogenesis of sarcopenia in cirrhosis has three major contributory causes: inadequate 
dietary intake, metabolic disturbance and malabsorption. There are several factors responsible for 
an altered dietary intake in patients with cirrhosis. Some report nausea, early satiety and loss of 
appetite. This commonly depends on the presence of ascites, upregulation of leptin and tumor 
necrosis factor-α [10] and zinc deficiency, which is usually responsible for altered taste sensation 
[11]. Altered visceral motility, and the overgrowth of small intestinal bacteria are also very common 
[12]. Sodium restriction, decreased protein intake and iatrogenic fasting during hospitalization 
contribute to aggravating poor oral intake (Figure 1). 
 
Figure 1. The pathogenesis of sarcopenia in patients with cirrhosis.
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As previously described, the liver plays a critical role in the body’s metabolic homeostasis and
especially in the synthesis and storage of glycogen. The cirrhotic liver tissue loses the capacity for this
physiological function with increasing decompensation, resulting in the breakdown of fat and muscle
and finally in the promotion of gluconeogenesis from non-carbohydrate sources [13]. This process leads
to muscle wasting. Malabsorption of nutrients in patients with cirrhosis may also be a consequence
of chronic pancreatitis, as a result of alcohol abuse, or intraluminal bile acid deficiency, because of its
decreased production, and overgrowth of bacteria in the intestine [14]. Paradoxically, sarcopenia may
also be related to obesity, particularly in the context of NAFLD cirrhosis. Indeed, there are frequent
citations in the current literature describing this co-morbidity condition. The prevalence of this
condition, also known as sarcopenic obesity is more frequent in women than in men, with a reported a
range from 4% to 84% in men and from 4% to 94% in women [15]. Moreover obesity is known to be
closely related to hepatic steatosis [4]. Several recent studies showed a relation between low skeletal
muscle mass and fatty liver [4]. Insulin resistance is linked both with excess fat tissue and sarcopenia,
given that skeletal muscle is one of the major target tissues of insulin action [4]. However, insulin
resistance is not the only factor involved in the development of hepatic steatosis and other hormones
have effects on body composition, lipid and glucose homeostasis. Growth hormone (GH) and insulin-
like growth factor 1 (IGF-1) may be involved and this could explain the interrelationship between liver
steatosis and sarcopenia [4]. Several studies showed how GH secretion is blunted in obese subjects,
with GH and IGF-1 linked to fatty infiltration of the liver [4]. Moreover, ectopic fat deposition has
proven to be associated with reduced GH levels. Impairment in GH production occurring with aging
is one of the factors causing the changes in body fat and muscle compartments leading to both excess
adiposity and sarcopenia [4].
Although sarcopenia is important as a prognostic factor in the clinical setting of liver disease,
current prognostic clinical scores do not include sarcopenia and are not completely satisfying. A recent
study indicates that sarcopenia is present in almost one half of patients with cirrhosis evaluated for
liver transplantation [16] and that it is independently associated with a twofold risk of mortality.
Thus, several authorities have proposed the modification of MELD (Mayo End stage Liver Disease) to
include sarcopenia (MELD-sarcopenia), given that its inclusion is associated with improvement in the
prediction of mortality in patients with cirrhosis [17].
3. Physical Activity
Exercise training has to be planned according to strength and resistance, flexibility and
balance/gait training of the body [18]. Given that exercise capacity in patients with cirrhosis is
reduced, regimens must be tailored for gradual exercise increments [19]. One of the main concerns
with respect to physical activity in patients with cirrhosis is the risk of causing complications of the
underlying liver disease [16].
Nevertheless, it is clear that muscle wasting increases fatigue, reducing the possibility of practising
physical exercise and finally leading to the worsening of sarcopenia through inactivity (Figure 2).J. Funct. Morphol. Kinesiol. 2016, 1,ge  4 of 8 
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As previously stated, the mechanisms responsible for these changes are related to protein synthesis
and metabolic alteration, leading to sarcopenia and cardiomyopathy. To this end, patients with cirrhosis
demonstrate a decreased cardiac response to exercise [19]. Moreover, the severity of liver disease
appears to be related to the extent and severity of sarcopenia and cardiomyopathy and finally to
a consequent reduction in exercise capacity [19]. Despite this evidence and the decreased exercise
capacity and muscle strength in patients with cirrhosis of the liver, it also seems that the only single
useful intervention in the treatment of muscle wasting in sarcopenia is physical activity. No other
therapeutic interventions are known. Exercise training attenuates or even reverses the process of muscle
wasting, thanks to anti-inflammatory and anti-oxidative effects able to oppose the pathways associated
with protein degradation [6]. Exercise training programs have been performed in patients with
autoimmune hepatitis in clinical remission while receiving immunosuppressive therapy. The physical
training was well tolerated, since the clinical condition did not worsen, and physical performance
capacity improved [20]. In a recent study, patients with cirrhosis underwent a moderate intensity
exercise program, although this uncovered previous complications of cirrhosis in those who were
otherwise compensated at the time of the study. Other studies reported that in patients with portal
hypertension not undergoing beta-blockers therapy, exercise could lead to an increased risk of variceal
bleeding through an increase in portal pressure [21]. However, subjects with previous variceal bleeding
or with large esophageal varices on secondary or primary bleeding prophylaxis with β-blockers and/or
variceal ligation did not present adverse effects from the exercise programme [16]. Patients undertook
a 12-week exercise program of treadmill walking and cycle ergometry, consisting of 1-h sessions,
three days a week, similar to programs used in other studies on patients affected by chronic heart or
respiratory disease [16]. The moderate exercise programme associated with leucine supplementation
improved exercise capacity, leg muscle mass and quality of life. Basal exercise capacity was significantly
impaired due to decreased muscle strength, deconditioning, fatigue, neuropsychiatric factors and
cardiorespiratory impairment secondary to hepatopulmonary syndrome or hepatic cardiomyopathy.
Another interesting and recent survey performed in a Japanese cohort showed how walking
5000 or more steps per day and maintaining a total energy intake of approximately 30 kcal/ideal
bodyweight may be a goal sufficiently great to prevent sarcopenia in compensated cirrhosis patients.
The study showed that both of these targets have to be reached in order to secure an energy intake
sufficient for synthesis of body protein. Moreover, this standard of physical activity is necessary
to maintain and increase skeletal muscle mass [22]. Nevertheless, it should be highlighted that
performing physical activity with insufficient nutrients and proteins intake could be detrimental in
patients with decompensated cirrhosis, since it could promote further protein catabolism and loss
of muscle mass. Thus, a proper nutritional assessment and supplementation are necessary before
initiating exercse programs in such patients. It should be noted, however, that patients with ascites and
marked stimulation of vasoconstrictor systems (renin-aldosterone and sympathetic nervous systems),
could have an impairment of renal function after exercise. Nevertheless, a tailored, adapted physical
activity program (cycloergometry + muscle strengthening according to ventilatory threshold) for
12 weeks seems feasible and sufficiently safe in patients awaiting liver transplant [21].
4. Nutrition
Food intake is commonly decreased in patients with advanced liver disease due to the presence
of nausea, early satiety, anorexia, vomiting and drug use [2]. Malnutrition is a frequent complication
in patients with cirrhosis of the liver and is also an important prognostic factor [2].
The assessment of nutritional status is also necessary for the treatment of patients with end-stage
liver disease [5]. In such patients, undernutrition is caused by poor dietary intake, malabsorption,
impaired protein synthesis, and acceleration of protein breakdown, which lead to the development of
sarcopenia. Negative EB is highly prevalent among patients on the waiting list for liver transplants,
and is also associated with the severity of liver disease. A recent research study demonstrated that low
food intake is the principal factor responsible of this negative EB [2].
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People with chronic liver disease show alterations in energy metabolism, resulting in amino
acid oxidation and protein deficiency [3]. Moreover end-stage liver disease patients exhibit early
onset of gluconeogenesis after short-term fasting, due to the decreased ability to store glycogen
as a consequence of reduced liver function. This accelerates the metabolic reaction to starvation
and explains the increased protein requirements and muscle depletion of those with established
cirrhosis [23]. Additionally, fat-soluble vitamin deficiencies and diminished reserves are related to
cirrhosis of the liver, and this results in an increased severity of both end-stage liver disease and
sarcopenia [3,24,25].
Both anorexia and obesity worsen sarcopenia. Anorexia and a reduced dietary intake decrease
the nutritional components which are essential for movement, while obesity contributes to worsening
sedentary life. Nevertheless, a fatty and rich diet associated to physical inactivity lead to the formation
of fat deposits, which are also able to produce proinflammatory adipokines, and inflammatory
consequences, such as a catabolic effect on muscle mass [26–29]. Both anorexia and obesity finally
lead to the loss of metabolically active components accompanied by an impaired body energy balance
(Figure 3).
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Figure 3. The effects on body energy balance of impaired dietary intake.GH: Growth hormone; IGF-1:
insulin- like growth factor 1, “Ò”: increase; “Ó” decrease.
This process is also worsened with aging where lean muscle mass changes [27]. In patients with
cirrhosis, obesity is closely linked to fatty liver and insulin resistance, and can accelerate hepatic
decompensation, enhance hepatocarcinogenesis, and result in poor patient survival. Thus, nutrition
management is imperative for obese patients with cirrhosis [24]. As previously stated, sarcopenia
is more frequent in women than in men due to reduced muscle mass in women and lower muscle
strength compared to men, and finally a major predisposition to accumulate body fat [15].
In cirrhosis, the nutritional status must be accurately assessed in the individual patient in order
to tailor the nutritional intervention, prevent complications and improve survival and quality of
life. Amodio et al. recently published some nutritional recommendations [30]. According to these
recommendations, hepatotoxic agents, such as alcohol, should be avoided and the correct daily energy
intake should be approximately about 35–40 kcal/kg body weight, distributed in 4–6 meals per day,
enough to restore and maintain nutritional status and help liver regeneration. Protein intake should be
about 1.2–1.5 g/kg body weight, according to the severity of undernutrition. Since cirrhotic patients
are predisposed to entering a starvation state after a relatively short fasting period, small and frequent
meals (“nibbling” pattern), rather than a small number of large meals (“gorging” pattern), is considered
preferable to maintain optimal energy metabolism [23]. Indeed, this pattern of meals throughout the
day and a late-night snack of complex carbohydrates can help in minimizing gluconeogenesis from
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protein utilization [31,32]. Moreover, a randomized controlled trial in cirrhosis patients suggested
that nocturnal energy supplementation may be superior to daytime energy supplementation for
protein accretion [33]. A lack of branched chain amino acids (BCAAs) in cirrhotic patients can
worsen muscular protein catabolism, decrease the synthesis of albumin, and is associated with hepatic
encephalopathy [23]. The oxidative use of glucose by skeletal muscle is regulated by BCAAs through
the stimulation of glucose recycling via the glucose-alanine cycle [23]. In particular, leucine seems to
play a crucial role in carbohydrate metabolism [34]. Skeletal muscle tissue is also crucial for the removal
of plasma ammonia and, in turn, hyperammoniemia impairs skeletal muscle synthesis, contributing to
worsening of sarcopenia and hepatic encephalopathy. In a recent study, the effects of leucine alone
or in combination with physical activity (15 min at 10 cm/s) every other day for five weeks were
tested in a rat model of cirrhosis. Leucine treated rats showed an improvement in muscle mass and
metabolic activity, further ameliorated by exercise, beyond an improved cognitive and psychomotor
function [21]. Minerals also have a great importance in a correct diet and zinc, magnesium and
selenium in particular [30]. Reduced levels of sodium have a detrimental effect on brain function,
contributing to hepatic encephalopathy. Moreover dietary sodium restriction is usually prescribed
to patients with ascites, although the poor evidence for this recommendation. Sodium intake should
not be less than 60 mmol/day, because otherwise the diet becomes unpalatable, compromising total
energy and protein intakes. Hyponatremia is more likely to occur when the intake of sodium is low,
while the intake of water is maintained or increased. Thus, careful monitoring of sodium and water
balance is required [30].
5. Conclusion
Sarcopenia is a common complication in people afflicted by cirrhosis of the liver, owing to a great
number of mechanisms that contribute to muscle wasting. Among these, a reduced nutrient intake
is associated with decreased taste sensation and appetite, nausea and early satiety, but also dietary
restrictions in sodium and water in order to prevent fluid accumulation. Undernutrition and physical
inactivity worsen the clinical course of patients with cirrhosis, leading to sarcopenia. Several studies
confirm the important role played by physical activity and balanced nutrition in chronic liver disease.
Tailored exercise and nutritional intervention should be strongly recommended in these patients in
order to improve people’s quality of life.
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